J Wouter Jukema
Overview
Explore the profile of J Wouter Jukema including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
852
Citations
40754
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ao L, van Heemst D, Jukema J, Rensen P, Willems van Dijk K, Noordam R
J Lipid Res
. 2025 Mar;
:100778.
PMID: 40089107
Background: Plasma 1-H nuclear magnetic resonance (H-NMR) metabolomic measures have yielded significant insight into the pathophysiology of cardiometabolic disease, but their interrelated nature complicates causal inference and clinical interpretation. This...
2.
Roselli C, Surakka I, S Olesen M, Sveinbjornsson G, Marston N, Choi S, et al.
Nat Genet
. 2025 Mar;
57(3):539-547.
PMID: 40050429
Atrial fibrillation (AF) is the most common heart rhythm abnormality and is a leading cause of heart failure and stroke. This large-scale meta-analysis of genome-wide association studies increased the power...
3.
van Oort M, Bingen B, Oliveri F, Al Amri I, Phagu A, Claessen B, et al.
Catheter Cardiovasc Interv
. 2025 Mar;
PMID: 40038885
Background: Intravascular lithotripsy (IVL) is increasingly used to treat coronary artery calcification (CAC). This study aimed to identify clinical and procedural factors associated with IVL treatment success. Methods: This retrospective...
4.
Henry A, Mo X, Finan C, Chaffin M, Speed D, Issa H, et al.
Nat Genet
. 2025 Mar;
PMID: 40038546
Heart failure (HF) is a major contributor to global morbidity and mortality. While distinct clinical subtypes, defined by etiology and left ventricular ejection fraction, are well recognized, their genetic determinants...
5.
Schwartz G, Szarek M, Reijnders E, Jukema J, Bhatt D, Bittner V, et al.
Eur J Prev Cardiol
. 2025 Feb;
PMID: 39921475
Aims: Apolipoprotein (Apo) C3 has been associated with incident coronary heart disease and major adverse cardiovascular events (MACE). Whether ApoC3 levels predict risk in patients with acute coronary syndrome (ACS)...
6.
Schwartz G, Szarek M, Jukema J, Cobbaert C, Reijnders E, Bittner V, et al.
Diabetes Care
. 2025 Feb;
PMID: 39913634
Objective: Previous genetic and clinical analyses have associated lower lipoprotein(a) and LDL cholesterol (LDL-C) with greater risk of new-onset type 2 diabetes (NOD). However, PCSK9 inhibitors such as alirocumab lower...
7.
Inia J, van Nieuwkoop-van Straalen A, Jukema J, Rolin B, Staarup E, Mogensen C, et al.
J Lipid Res
. 2025 Feb;
66(3):100753.
PMID: 39909173
Atherosclerosis is the major cause of cardiovascular disease. This study evaluated the effect of lipid lowering using a novel peptide inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) and a monoclonal...
8.
Choi S, Young R, Koyama S, Jukema J, Trompet S, Ford I, et al.
JACC Adv
. 2025 Jan;
4(2):101535.
PMID: 39886309
No abstract available.
9.
Neijenhuis R, Nederend M, van Groningen A, Jongbloed M, Vliegen H, Jukema J, et al.
Open Heart
. 2025 Jan;
12(1).
PMID: 39884739
Background: Short-term improvements in quality of life (QOL) have been reported in adult congenital heart disease patients with systemic right ventricle (sRV) failure after treatment with sacubitril/valsartan. This study aimed...
10.
Anwar H, Lopez Santi P, Algowhary M, Abdelmegid M, Helmy H, Jukema J, et al.
Int J Cardiol Heart Vasc
. 2025 Jan;
56:101595.
PMID: 39867853
Background: Epicardial fat tissue (EFT) is an active organ that can affect cardiac function and structure through endocrine, paracrine, and proinflammatory mechanisms. We hypothesized that greater thickness of EFT may...